<a href="https://laohu8.com/S/TXG">10x Genomics</a> posts Q3 revenue of $149 million and net loss of $27.5 million
10x Genomics reported third quarter 2025 revenue of $149.0 million, a 2% decrease from the same period in 2024, mainly due to lower instrument revenue. Excluding a one-time license and royalty revenue of $27.3 million in the previous quarter, third quarter revenue increased 2% sequentially. The company posted an operating loss of $32.2 million, compared to $41.5 million a year earlier, and a net loss of $27.5 million, down from $35.8 million in the prior year period. Cash, cash equivalents, and marketable securities totaled $482.1 million at the end of the quarter, up $35 million from the previous quarter. Notable business developments included the launch of the next-generation Chromium Flex for scalable single cell analysis and Xenium Protein, a spatial multiomic workflow for simultaneous RNA and protein detection. For the fourth quarter of 2025, 10x Genomics expects revenue between $154 million and $158 million, representing a 6% decline from the prior year period and 5% sequential growth at the midpoint.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA18024) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.